The definition of metabolic dysfunction associated fatty liver disease (MAFLD) is based on the evidence of hepatic steatosis, and the coexistence of overweight/obesity, or type 2 diabetes mellitus or the coexistence of two other risk factors related to metabolic dysregulation (waist circumference ≥102/88 cm in white men/women, low HDL-cholesterol, increase in serum triglyceride levels > 150 mg/dl, blood pressure >130/85, prediabetes, plasma C-reactive protein (CRP) >2.5, homeostatic model assessment (HOMA) score >2.5) (2). This evidence concerns the gene CRP and Hepatic steatosis.